Global Absorbable Heart Stent Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Absorbable Heart Stent Market Size

• The global absorbable heart stent market size was valued at USD 487.98 million in 2025 and is expected to reach USD 1,071.40 million by 2033, at a CAGR of 10.33% during the forecast period
• The market growth is largely fueled by the increasing prevalence of cardiovascular diseases, rising preference for minimally invasive procedures, and ongoing technological advancements in absorbable stent materials and design, which together are enhancing clinical outcomes and expanding treatment adoption worldwide
• Furthermore, growing awareness of the long‑term benefits of absorbable stents such as reduced risk of chronic complications compared with permanent metallic implants along with greater healthcare infrastructure investment in emerging economies is driving strong demand for advanced cardiac care solutions and positioning absorbable heart stents as a preferred choice in modern interventional cardiology.

Absorbable Heart Stent Market Analysis

• Absorbable heart stents, providing temporary scaffolding to arteries and gradually dissolving after restoring blood flow, are increasingly vital in modern interventional cardiology due to their ability to reduce long-term complications, improve vascular healing, and allow flexibility for future treatments
• The escalating demand for absorbable heart stents is primarily fueled by the rising prevalence of cardiovascular diseases, growing preference for minimally invasive procedures, and continuous advancements in stent materials and designs that enhance safety, efficacy, and patient outcomes
• North America dominated the absorbable heart stent market with the largest revenue share of 42.5% in 2025, characterized by advanced healthcare infrastructure, high adoption of innovative cardiovascular devices, and a strong presence of leading medical device manufacturers, with the U.S. experiencing substantial growth in coronary interventions driven by regulatory approvals, clinical innovations, and increasing cardiac procedure volumes
• Asia-Pacific is expected to be the fastest-growing region in the absorbable heart stent market during the forecast period due to rising cardiovascular disease prevalence, expanding healthcare facilities, growing awareness of minimally invasive cardiac procedures, and increased investments in advanced cardiac care
• The polymer segment dominated the market with a market share of 46.3% in 2025, owing to its superior biocompatibility and biodegradability

Report Scope and Absorbable Heart Stent Market Segmentation     

Absorbable Heart Stent Market Trends

Advancements in Bioresorbable Stent Technology

• A major and accelerating trend in the global absorbable heart stent market is the development of next-generation bioresorbable stents with improved drug-eluting properties and optimized scaffold design, enhancing patient safety and long-term outcomes
  • For instance, the Absorb GT1 Bioresorbable Vascular Scaffold allows gradual vessel healing while minimizing late stent thrombosis risk, offering interventional cardiologists a reliable alternative to permanent metallic stents
• Technological innovations enable features such as thinner strut designs and improved radial strength, improving procedural success rates and reducing complications, while allowing vessels to regain natural function over time
• Integration with advanced imaging techniques such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) facilitates precise deployment, reducing procedural errors and improving clinical outcomes
• The trend towards more biocompatible, temporary scaffolding devices is fundamentally reshaping physician and patient expectations for coronary interventions, promoting wider adoption in complex and high-risk cases
• The demand for stents with enhanced bioresorbable technology is growing rapidly across both developed and emerging markets, as healthcare providers seek solutions that combine efficacy, safety, and long-term vessel restoration
• Development of patient-specific stent designs using 3D imaging and computational modeling is gaining traction, enabling personalized therapy and improved clinical outcomes
• Increasing collaborations between stent manufacturers and academic research institutions are accelerating R&D, resulting in novel stent materials and coatings that enhance performance and reduce complications

Absorbable Heart Stent Market Dynamics

Driver

Rising Prevalence of Cardiovascular Diseases and Minimally Invasive Procedures

• The increasing prevalence of coronary artery disease and other cardiovascular conditions, combined with a preference for minimally invasive procedures, is a major driver for the growing demand for absorbable heart stents
  • For instance, in March 2025, Abbott Laboratories reported rising utilization of its bioresorbable stents in complex coronary interventions, reflecting clinical adoption trends in both hospitals and cardiac centers
• As patients seek safer long-term outcomes with fewer complications, absorbable stents offer advantages over permanent metallic implants, including reduced risk of late thrombosis and restoration of natural vessel function
• Furthermore, expanding awareness of advanced cardiac interventions and increased physician training in bioresorbable stent deployment are making these devices a preferred choice in modern interventional cardiology
• Hospitals and cardiovascular centers are increasingly investing in bioresorbable stents, supporting higher procedural volumes and adoption rates, particularly in regions with rising cardiovascular disease burden
• Increasing government initiatives and reimbursement support for minimally invasive cardiovascular procedures are facilitating market growth, especially in developed countries
• Rising patient preference for stents that allow future interventional flexibility, such as the ability to perform bypass grafts or additional PCI procedures, is further driving adoption of absorbable stents

Restraint/Challenge

High Cost and Limited Long-Term Clinical Data

• The relatively high cost of absorbable heart stents compared with traditional metallic stents poses a significant challenge to widespread adoption, particularly in price-sensitive markets and developing regions
  • For instance, delayed reimbursement approvals in certain countries have slowed the uptake of bioresorbable stents despite proven short-term efficacy, creating market entry barriers for new manufacturers
• Concerns about limited long-term clinical data and procedural complexity make some physicians cautious, affecting adoption rates even in advanced healthcare settings
• Addressing these challenges through clinical studies, cost reductions, and physician education is crucial for building confidence and expanding the market reach of bioresorbable stents
• While technological improvements continue, overcoming affordability and data limitations will be key to achieving sustained growth, particularly in emerging economies with growing cardiovascular disease prevalence
• Strict regulatory requirements for safety, efficacy, and quality of bioresorbable stents can delay product approvals, affecting market entry timing for new players
• Potential complications such as scaffold thrombosis or incomplete resorption in certain patient groups remain a concern, requiring ongoing monitoring and caution from healthcare providers

Absorbable Heart Stent Market Scope

The market is segmented on the basis of material type, application, and end user.

• By Material Type

On the basis of material type, the absorbable heart stent market is segmented into metal and polymer. The polymer segment dominated the market with a largest market revenue share of 46.3% in 2025, driven by its superior biocompatibility and biodegradability. Polymer stents are preferred by physicians for their ability to gradually dissolve after restoring vessel patency, reducing long-term complications such as late stent thrombosis. The segment benefits from growing clinical evidence supporting the safety and efficacy of polymer-based scaffolds. Polymer stents also allow for better drug-eluting capabilities, improving post-procedure outcomes in patients with coronary artery disease. Hospitals and cardiovascular centers increasingly adopt polymer stents due to their favorable procedural success rates and reduced risk profiles. The segment’s dominance is further supported by continuous R&D aimed at improving polymer stent mechanical strength and degradation time.

The metal segment is expected to witness the fastest growth rate of 10.5% from 2026 to 2033, fueled by innovations in biodegradable metallic alloys such as magnesium and iron-based scaffolds. These stents provide improved radial strength and easier handling during deployment, making them suitable for complex coronary and peripheral interventions. Metal-based absorbable stents offer a balance between mechanical performance and temporary scaffolding, appealing to interventional cardiologists who seek reliable procedural outcomes. Growing adoption in emerging markets is further accelerating the segment’s growth due to increasing cardiovascular disease prevalence and expanding hospital infrastructure. Regulatory approvals and clinical studies validating the safety of bioresorbable metal stents are also boosting confidence among physicians and patients. In addition, collaborations between manufacturers and research institutions are driving faster commercialization of advanced metal stent designs.

• By Application

On the basis of application, the market is segmented into coronary artery disease (CAD) and periphery artery disease (PAD). The coronary artery disease segment dominated the market with the largest revenue share in 2025, owing to the high incidence of CAD globally. Absorbable stents are particularly advantageous in coronary interventions because they restore vessel patency while reducing long-term complications associated with permanent metallic stents. Clinical adoption is further driven by strong procedural success rates and positive long-term patient outcomes reported in major trials. Hospitals and cardiovascular centers prefer CAD stents due to their established efficacy in percutaneous coronary interventions (PCI) and ability to accommodate complex lesion types. The demand is also supported by increasing awareness among patients and physicians regarding minimally invasive cardiac procedures. Continuous technological improvements, such as thinner struts and drug-eluting coatings, enhance stent performance in CAD cases, reinforcing market dominance.

The periphery artery disease segment is expected to witness the fastest growth from 2026 to 2033, driven by increasing incidence of peripheral arterial occlusions and the growing adoption of minimally invasive procedures in peripheral interventions. Absorbable stents in PAD allow temporary scaffolding of peripheral vessels, reducing the risk of chronic complications and improving limb salvage rates. Technological advancements in stent flexibility and radial strength make these devices suitable for complex vascular anatomies. Rising awareness of peripheral vascular diseases, combined with improved hospital infrastructure and trained specialists in emerging economies, is accelerating adoption. Research initiatives targeting PAD treatment optimization are also contributing to faster growth in this application segment. Furthermore, reimbursement support and healthcare funding for peripheral interventions are expected to further boost market expansion.

• By End User

On the basis of end user, the market is segmented into hospitals and clinics, cardiovascular centers, research institutes and organizations, and others. The hospitals and clinics segment dominated the market with the largest revenue share in 2025, as these facilities perform the majority of percutaneous coronary and peripheral interventions. Hospitals and clinics prefer absorbable stents due to their ability to improve patient outcomes, reduce complications, and support a broad range of cardiovascular procedures. Large hospital networks benefit from streamlined procurement processes and strong relationships with stent manufacturers, ensuring consistent supply of advanced devices. The dominance is also reinforced by rising procedure volumes, increased patient awareness, and growing demand for minimally invasive treatment options. In addition, hospitals have the resources to adopt the latest bioresorbable stent technologies and provide necessary follow-up care, further driving market share.

The cardiovascular centers segment is expected to witness the fastest growth from 2026 to 2033, fueled by the increasing specialization of cardiac care and rising number of dedicated intervention centers. Cardiovascular centers focus on complex procedures such as high-risk coronary interventions and peripheral stenting, creating demand for advanced bioresorbable stents. Continuous investment in state-of-the-art equipment and highly skilled cardiologists enables adoption of innovative stent technologies. The segment’s growth is also supported by expanding treatment awareness and patient referrals from general hospitals. Regulatory support and insurance coverage for specialized cardiac interventions further facilitate market penetration. Collaborations with stent manufacturers for clinical trials and training programs are expected to sustain rapid growth in this segment.

Absorbable Heart Stent Market Regional Analysis

• North America dominated the absorbable heart stent market with the largest revenue share of 42.5% in 2025, characterized by advanced healthcare infrastructure, high adoption of innovative cardiovascular devices, and a strong presence of leading medical device manufacturers
• Physicians and hospitals in the region highly value the safety, efficacy, and reduced long-term complications offered by absorbable stents, as well as their ability to restore natural vessel function compared with permanent metallic stents
• This widespread adoption is further supported by strong healthcare funding, well-established cardiovascular centers, high procedural volumes, and increasing awareness of bioresorbable stent benefits, establishing these devices as a preferred solution for both coronary and peripheral interventions

U.S. Absorbable Heart Stent Market Insight

The U.S. absorbable heart stent market captured the largest revenue share of 78% in 2025 within North America, fueled by the high prevalence of coronary artery disease and advanced cardiovascular care infrastructure. Hospitals and cardiovascular centers are increasingly adopting bioresorbable stents due to their reduced long-term complications and improved procedural outcomes. The growing preference for minimally invasive cardiac procedures, combined with physician expertise and widespread awareness of bioresorbable stent benefits, further propels market growth. Moreover, ongoing clinical trials and regulatory approvals for next-generation polymer and metal stents are significantly contributing to the expansion of the U.S. market.

Europe Absorbable Heart Stent Market Insight

The Europe absorbable heart stent market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by the rising prevalence of cardiovascular diseases and the need for advanced interventional cardiology solutions. Increased urbanization and awareness of minimally invasive procedures are fostering adoption. Hospitals and cardiovascular centers across Germany, France, and Italy are integrating absorbable stents into coronary and peripheral interventions. In addition, favorable healthcare policies, reimbursement frameworks, and strong clinical evidence supporting bioresorbable stent efficacy are driving growth across both public and private healthcare facilities.

U.K. Absorbable Heart Stent Market Insight

The U.K. absorbable heart stent market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by the increasing incidence of coronary artery disease and the trend toward minimally invasive cardiac interventions. Concerns regarding post-stent complications and long-term outcomes are encouraging hospitals and cardiovascular centers to adopt bioresorbable stents. The U.K.’s well-developed healthcare infrastructure, alongside growing awareness among cardiologists and patients about the benefits of bioresorbable scaffolds, is expected to continue to stimulate market growth.

Germany Absorbable Heart Stent Market Insight

The Germany absorbable heart stent market is expected to expand at a considerable CAGR during the forecast period, fueled by increasing awareness of cardiovascular health and the adoption of advanced interventional procedures. Germany’s highly developed healthcare infrastructure and emphasis on innovation support the integration of bioresorbable stents into routine practice. Hospitals and cardiovascular centers are leveraging these stents for both coronary and peripheral interventions, while ongoing clinical research and government-backed healthcare initiatives are further promoting market expansion.

Asia-Pacific Absorbable Heart Stent Market Insight

The Asia-Pacific absorbable heart stent market is poised to grow at the fastest CAGR of 11.5% during 2026–2033, driven by increasing cardiovascular disease prevalence, rapid urbanization, and rising healthcare investments in countries such as China, Japan, and India. The growing inclination toward minimally invasive procedures and bioresorbable technology adoption is fueling demand. Furthermore, expanding hospital infrastructure, increasing awareness among cardiologists, and government initiatives supporting advanced cardiac care are enabling wider access to absorbable stents in the region.

Japan Absorbable Heart Stent Market Insight

The Japan absorbable heart stent market is gaining momentum due to the country’s technologically advanced healthcare system, aging population, and growing focus on minimally invasive cardiac interventions. Hospitals and cardiovascular centers emphasize improved patient outcomes and reduced long-term complications through bioresorbable stent adoption. Integration with advanced imaging systems and ongoing clinical trials for next-generation stents are further driving market growth in both coronary and peripheral applications.

India Absorbable Heart Stent Market Insight

The India absorbable heart stent market accounted for the largest market revenue share in Asia-Pacific in 2025, attributed to the expanding middle-class population, increasing cardiovascular disease prevalence, and rapid healthcare infrastructure development. Hospitals and cardiovascular centers are adopting bioresorbable stents for coronary and peripheral interventions due to their clinical benefits and growing physician familiarity. Government initiatives supporting minimally invasive procedures, coupled with the availability of cost-effective stent options and growing domestic manufacturing, are key factors propelling market growth in India.

Absorbable Heart Stent Market Share

The Absorbable Heart Stent industry is primarily led by well-established companies, including:

• Abbott (U.S.)
• Boston Scientific Corporation (U.S.)
• Medtronic (Ireland)
• BIOTRONIK SE & Co. KG (Germany)
• Terumo Medical Corporation (Japan)
• MicroPort Scientific Corporation (China)
• Elixir Medical Corporation (U.S.)
• Medinol Ltd. (Israel/U.S.)
• Meril Life Sciences Pvt. Ltd. (India)
• Reva Medical, Inc. (U.S.)
• Amaranth Medical (U.S.)
• Arterial Remodeling Technologies (U.S.)
• Lepu Medical Technology (China)
• C R Bard, Inc. (U.S.)
• B. Braun SE (Germany)
• Terumo Interventional Systems (Japan/U.S.)
• Biosensors International Group, Ltd. (Singapore)
• Cardinal Health (U.S.)
• Cook (U.S.)

What are the Recent Developments in Global Absorbable Heart Stent Market?

• In June 2025, StentIt launched a first‑in‑human trial of its bioresorbable stent to treat below‑the‑knee chronic limb‑threatening ischemia (CLTI),* representing an important clinical milestone for next‑gen bioresorbable scaffolds targeting a severe form of PAD with potential to expand interventional options beyond current therapies
• In February 2025, BIOTRONIK began the BIOMAG‑LL pre‑market trial to assess the safety and clinical performance of its Freesolve® resorbable magnesium scaffold for treating long lesions in native coronary arteries, positioning it for broader clinical adoption in complex cases
• In July 2024, MicroPort Scientific Corporation announced that its Firesorb® fully bioresorbable cardiac stent received official market approval from China’s National Medical Products Administration (NMPA), highlighting exceptional clinical performance and a low rate of major adverse events, marking a milestone for next‑generation dissolving heart stent technologies
• In April 2024, Abbott’s Esprit™ BTK Everolimus Eluting Resorbable Scaffold System received FDA approval for treatment of below‑the‑knee (BTK) chronic limb‑threatening ischemia (CLTI),* marking the first dissolving stent approved for peripheral artery disease (PAD) below the knee and offering a drug‑eluting resorbable solution that dissolves after supporting vessel healing post‑intervention
• In March 2024, BIOTRONIK’s Freesolve™ resorbable magnesium scaffold received CE approval and was launched in Europe, marking the expansion of metallic bioresorbable scaffold options designed for improved vessel support and complete magnesium absorption within about 12 months

SKU-61023